While the United States population under the age of 65 has tripled since the beginning of the last century, the number of those over age 65 has increased 11-fold. At present, 1 in 8 Americans (33.2 million) are over age 65, up from 1 in 25 in 1900 (3.1 million). This trend is expected to continue. Projections by the US Census Bureau indicate that the elderly population will more than double between now and the year 2050, to 80 million, when it is estimated that 1 in 5 Americans will be elderly.\(^1\) The prevalence of dementia rises steeply with age, doubling every 4 to 5 years from the age of 60, so that more than one third of individuals over 80 years of age are likely to have dementia.\(^2\) With increased life expectancy in the United States continues to increase, the projected numbers of elderly people who will develop dementia will grow rapidly. This paper reviews four well-established cardiovascular risk factors (type 2 diabetes, hypertension, cholesterol, and inflammation), for which there is longitudinal epidemiological evidence of increased risk of dementia, Alzheimer’s disease, mild cognitive impairment, and cognitive decline. These risk factors are of special interest because of their potential modifiability, which may affect the course of cognitive compromise. Diabetes is the cardiovascular risk factor (CvRF) most consistently associated with cognition. Hypertension in midlife is consistently associated with cognition, but its associations with late-life hypertension are less clear. Total cholesterol is not consistently associated with cognition. Interleukin-6 and C-reactive protein are inflammatory markers relatively consistently associated with cognition. Composites of the CvRFs increase the risk for dementia in a dose-dependent fashion, suggesting a cumulative effect of these factors on neuronal stress. In the relatively few studies that have reported interactions of risk factors, they potentiate each other. The effect of each of these risk factors varies according to apolipoprotein E genotype. It may be that the effect of these risk factors varies according to the presence of the others, and these complex relationships underlie the biological mechanisms of cognitive compromise. This may be crucial for understanding the effects on cognition of drugs and other approaches, such as lifestyle change, for treating these risk factors.

© 2009, LLS SAS

Dialogues Clin Neurosci. 2009;11:201-212.
expectancy in the United States, the projected numbers of elderly people who will develop dementia will grow rapidly. There are no cures or preventive measures yet for dementia.

Alzheimer’s disease (AD) remains the most common cause of dementia in the elderly. The risk factors for AD, other than age, include female gender, family history, and at least one apolipoprotein E4 (APOE4) allele. In addition, cardiovascular risk factors, established as risk factors for vascular dementia, have also been associated with AD. These risk factors are of special interest because of their potential modifiability so they may affect the course of disease. This paper reviews four well-established cardiovascular risk factors (type 2 diabetes, hypertension, cholesterol, and inflammation), for which there is longitudinal epidemiological evidence of increased risk of dementia, AD, mild cognitive impairment (MCI), and cognitive decline.

No two longitudinal epidemiological studies of dementia have the same methodology, and they each study distinct populations. Studies differ in when the risk factor is measured (eg, midlife vs closer to ascertainment of dementia), in the proportions of people carrying the risk factor, in the proportion of people being treated for the risk factor, the methods by which the risk factor was measured (eg, direct measure, self-report, medical charts), in the confounders accounted for, and of course, in the outcome measures (typically AD, vascular dementia, all cause dementia, MCI, or cognitive decline). For each cardiovascular risk factor, this paper summarizes its relationships with the cognitive outcomes. For each risk factor we tabulate the main results of longitudinal epidemiological studies of dementia, MCI, and cognitive decline, including nonsignificant in addition to significant results. Beyond separate effects of these risk factors, we consider multiple causes that may underlie the development of AD and dementia, by discussing combination effects—involving these risk factors with each other and with other factors—which particularly affect cognitive compromise.

**Type 2 diabetes**

Table I presents studies examining risks of dementia, MCI, and cognitive decline in patients with type 2 diabetes and demonstrates, relatively consistently, increased risks for each of these outcomes. Type 2 diabetes has been demonstrated to increase risk for dementia in most, but not all, prospective epidemiological studies, with the highest odds ratios approaching 3-fold increased risk of dementia for diabetic individuals compared with nondiabetics. Many studies have also shown increased risk for AD and VaD (eg, ref 30). A recent study suggests that type 2 diabetes or impaired fasting glucose might be present in up to 80% of patients with AD. A systematic review of the effect of diabetes on dementia and cognitive decline concludes that these should be considered consequences and disabling manifestations of diabetes. Recently, even prediabetes (defined as glucose >7.8 mmol/L but <11.0 mmol/L) was associated with dementia (HR 1.77; 95% CI 1.02-3.12) and AD (HR 1.98; 1.12-

### Table I. Risk of dementia, MCI, and cognitive decline in patients with Type 2 diabetes.

| Reference       | Results (95% CI) |
|-----------------|------------------|
| **Dementia studies** |                  |
| Schnaider Beeri | OR 2.8 (1.4-5.7) |
| Brayne          | OR 2.6 (0.9-7.8) |
| Yaffe           | OR 2.4 (0.9-6.1) |
| Ott             | RR 1.9 (1.3-2.8) |
| Leibson         | SMR 1.6 (1.3-2.0) |
| Whitmer         | HR 1.5 (1.2-1.8) |
| Xu              | HR 1.5 (1.1-2.1) |
| Peila           | RR 1.5 (1.0-2.2) |
| Curb            | RR 1.4 (0.9-1.9) |
| MacKnight       | RR 1.3 (0.9-1.7) |
| Hassing         | RR 1.2 (0.8-1.7) |
| **MCI studies** |                   |
| Yaffe           | OR 1.8 (1.1-2.8) |
| Luchsinger      | HR 1.5 (1.0-2.3) |
| Luchsinger      | HR 1.4 (1.0-1.9) |
| **Cognitive decline** |                |
| Gregg           | OR 1.7 (1.3-2.4) |
| Logroscino      | OR 1.3 (1.1-1.6) |
| Fontbonne       | OR 1.2 >2 for 4 of 9 tests |
| Knopman         | 37% to 165% greater rate of cognitive decline in diabetics (depending on the test) |
| Okereke         | Diabetics decline faster; global cognition D-.09 (-.15, -.04) |
| Hassing         | Diabetics decline over twice as fast as non diabetics |
| Arvanitakis     | 44% greater rate of cognitive decline in diabetics |
| Hassing         | Diabetics decline twice as fast as nondiabetics |
| Van den Berg    | Diabetes not associated with cognitive decline |

202
3.50). A few epidemiological studies have examined the longitudinal association between diabetes and MCI, a state of cognitive compromise preceding AD or frank dementia, and all showed significantly increased risk for subjects with diabetes. Impaired fasting glucose, a prediabetic condition, was also associated with MCI. Numerous studies have reported consistently increased risk of cognitive decline in diabetes. Diabetes is a complex metabolic disorder that is closely associated with other risk factors for dementia, such as age, hypertension, and the metabolic syndrome—a clustering of several commonly occurring disorders (including abdominal obesity, hypertriglyceridemia, low high-density lipoprotein (HDL) level, and hypertension) that are often associated with diabetes. These risk factors, together with diabetes-specific characteristics (eg, age of onset, glycemic control, use of antidiabetes medications), demographic and socioeconomic factors, and genetic factors, might be important determinants of the increased risk of cognitive decline and dementia in individuals with diabetes. Co-occurrence of diabetes and hypertension greatly increases the risk of dementia and of cognitive decline. High systolic blood pressure interacted with borderline diabetes and with frank diabetes multiplying the risk of AD. Diabetes almost doubled the risk of dementia and AD in the Rotterdam study, but diabetics taking insulin were at the highest risk (RR 4.3, 1.7-10.5) suggesting that more severe diabetes increases dementia risk. Consistent with these observations, subjects with longer duration of diabetes or with diabetes complications had steeper cognitive decline.

The potential mediating effect of APOE4 genotype and of age in the relationship between diabetes and dementia is less clear. Participants with diabetes and the APOE4 allele had a risk ratio of 5.5 (CI 2.2-13.7) for AD compared with those with neither risk factors in the Honolulu Asia Aging Study, and this was consistent with neuropathological findings. However, borderline diabetes was associated with AD only in non-APOE4 carriers in the Kongsholmen study. The effect of age on the relationships between diabetes and dementia is also difficult to interpret. The relationship between diabetes and dementia in the Framingham study was strongest for participants older than 75 but diabetes was not associated with accelerated cognitive decline in 85+ years of age participants in another study. This suggests that factors other than CVRFs (ie, age, APOE genotype) interact with diabetes to increase the risk of cognitive compromise. Several potential mechanisms underlying the association between diabetes and dementia have been proposed:

- Diabetes is associated with micro- and/or macrovascular disease which in turn increase the risk of cognitive decline and dementia
- Defective insulin receptor signaling pathway (IRSP) in the central nervous system, the IRSP is associated with vital brain processes including synaptic plasticity, neuroprotection, neurodegeneration, survival, growth, energy metabolism, and longevity. Insulin receptors (IR) are abundant throughout the brain, and are expressed in especially high abundance in regions that support cognitive function. Aβ, the main component of neuritic plaques, hallmark lesions of AD, decreases insulin affinity and reduces the binding of insulin to its receptor preventing rapid activation of specific kinases required for multiple cellular functions, including long-term potentiation (LTP). Soluble Aβ oligomers were recently shown to significantly lower IR responses to insulin and to cause rapid and substantial loss of neuronal surface IRS. The IR desensitization found in AD brains, hampers the release of A, from the intracellular to the extracellular compartment, which may be a mechanism for its neurotoxicity.

- Advanced glycation end products (AGEs) may have a crucial role in the relationship between diabetes and dementia. AGEs, which normally increase with age and faster with diabetes, are the products of naturally occurring reactions between reducing sugars, eg, glucose, and free amine-containing proteins or lipids. AD brains have significantly higher levels of AGEs than normal controls, and in in-vitro studies, AGEs contribute to the formation of amyloid plaques and neurofibrillary tangles. Therefore, treatment for diabetes has the potential for salutary effects on cognitive compromise. In a 24-week randomized double blind trial, metformin, and its resulting improved glycemic control, were associated with improved memory. Rosiglitazone treatment of Tg2576 mice (transgenic mice overexpressing amyloid precursor protein) resulted in better spatial learning and memory abilities and an approximately 25% reduction in Aβ42 levels. Rosiglitazone therapy resulted in improved memory and selective attention while not affecting glucose levels in a study of 30 AD or MCI nondiabetic subjects during a period of 6 months. A trial with 518 mild-
to-moderate AD patients treated with rosiglitazone for 6 months reported significant improvement in cognition only in patients who did not possess an APOE4 allele. It should be noted that these encouraging results must be taken with caution in light of recent studies suggesting increased myocardial infarction and death from cardiovascular causes in rosiglitazone users. Craft et al have performed several investigations examining the effect of intravenous insulin in nondiabetic elderly adults with AD. Mild-to-moderate AD patients’ immediate and delayed recall were improved in hyperglycemic and hyperinsulinemic conditions compared with a saline control condition. However, normal controls had no change in their cognition. Intranasal insulin administration has recently shown some promising effects on memory. Substantially reduced neuritic plaques (NPs), the hallmark lesions of the AD brain, were found in the brains of diabetic subjects who during life received a combination of insulin and another antidiabetic medication. In a recent search of the literature by the Cochrane control trial register, however, no appropriate studies were found for meta-analysis regarding the effect of treatment for type 2 diabetes and degree of metabolic control on the development of dementia. Recently, the SALSA study reported decreased rates of cognitive decline in diabetic subjects receiving antidiabetic medications (insulin or oral hypoglycemic) compared with untreated diabetic subjects (but see refs 8,16). These studies are provocative and invite systematic investigation of the possible benefits of diabetes medications on cognition, but are not sufficient to draw conclusions.

**Hypertension**

The relationships of hypertension with dementia and cognitive decline are less straightforward, as shown in Table II. Several longitudinal studies suggest that elevated blood pressure levels or hypertension, both in midlife and closer to dementia ascertainment, are associated with increased risk of cognitive decline, MCI, dementia, and AD. However, some studies do not find these relationships or even find that low blood pressure is associated with increased risk suggesting the possibility of a U-shaped relationship between blood pressure and cognition. All the studies reporting negative or opposite results measured blood pressure closer to dementia ascertainment.

| Reference | Predictor | Results (95% CI) |
|-----------|-----------|-----------------|
| Whitmer | HTN in midlife | HR 1.24 (1.04-1.48) |
| Launer | BP in midlife | OR 4.3 (1.7-10.8) for DBP >95 mm Hg (compared with 80 to 89) and 4.8 (2.0-11.0) for SBP >160 (compared with 110-139) |
| Kivipelto | BP in midlife | OR 2.8 (1.1-7.2) for SBP >160 mm Hg and 2.3 (1.1-5.1) for DBP >95 |
| Kivipelto | BP in midlife | OR 2.3 (1.0-5.5) for SBP >160 mm Hg |
| Qiu | BP in late life | OR 1.6 (1.1-2.2) for SBP >180 mm Hg and OR 1.5 (1.0-2.1) for DBP <65 |
| Skoog | BP at the age of 70 | Participants developing dementia at the age of 79-85 had higher SBP and DBP 15 years earlier |
| Ruitenberg | BP in late life | RR 0.93 (0.88-0.99) per 10 mm Hg SBP and 0.89 (0.79-1.00) per 10 mm Hg DBP |
| Kalmijn | BP in midlife | RR 1.05 (0.91-1.21) for an increase of 1 SD of DBP and RR 1.07 (0.94-1.22) for SBP |
| Posner | BP in late life | BP was not associated with dementia 7 years later |
| Kivipelto | BP at midlife | OR 1.5 (0.8-2.0) for SBP >160 mm Hg |
| Tzourio | HTN in late life | OR 2.8 (1.6-5.0) for subjects with a drop > 4 points in the MMSE over 4 years |
| Knopman | HTN in late life | HTN was associated with greater decline in the digit symbol test but not with delayed recall or letter fluency |
| Mielke | BP in late life | SBP >160 mm Hg was associated with faster decline in CDR-SOB and MMSE. |
| Hebert | BP in late life | BP not associated with a 6-year change in global cognitive function |
| Posner | BP in late life | BP not associated with changes in memory, language, or general cognitive function |

Table II. Risk of dementia, MCI, and cognitive decline in patients with high blood pressure or a diagnosis of hypertension. OR, odds ratio; RR, relative risk; HR, hazard ratio; CDR-SOB, clinical dementia rating sum of boxes; SBP, systolic blood pressure; DBP, diastolic blood pressure; HTN, hypertension
taining, suggesting that: i) hypertension is a risk factor for dementia several decades later; and ii) high or low blood pressure are associated with incipient dementia. It has been suggested that the dementia process per se might affect blood pressure, adding a level of complexity to the directionality of the relationship between hypertension and dementia. In addition, the impact of this risk factor on cognition depends on age. Consistent with the latter, systolic blood pressure >160 at baseline was associated with steeper rates of cognitive decline in 85+ individuals (compared with younger hypertensive or oldest old individuals with lower systolic blood pressure) in the Cache County study. Another reason for differences among results is the effect of use of antihypertensive medication. For example, in the Honolulu Asia Aging Study, the association between high blood pressure and AD was strongest among those who were never treated for hypertension, while in the Kungsholmen Study low diastolic blood pressure was associated with incident AD and dementia, particularly in persons who used antihypertensive medication. Antihypertensive medication has been shown to be associated with reduced incidence of AD, and with reduced rates of cognitive decline in additional longitudinal studies. The effect of antihypertensive use on risk of dementia was particularly pronounced in APOE4 carriers in one study and in men with longer duration of antihypertensive medication use in another. Low diastolic blood pressure had a synergistic effect with APOE4 to significantly increase the risk of AD, but antihypertensive medication counteracted the deleterious effect of high systolic blood pressure in subjects with the APOE4 allele. Six placebo-controlled antihypertensive trials had dementia or cognitive decline as their secondary outcomes. Reduced risk of incident dementia was found in one study; other studies found reduced cognitive decline or dementia risk only in post hoc analysis. In a meta-analysis combining these data, the combined hazard ratio favored treatment (HR 0.87, CI 0.76-1.00).

Cerebrovascular disease resulting from hypertension is one major reason for increased risk of dementia and cognitive decline in hypertensive subjects. Additionally, direct relationships of hypertension with AD neuropathology have been found. Elevated systolic and diastolic blood pressure in midlife was associated with a greater number of NPs and neurofibrillary tangles (NFTs), respectively. Similarly, hypertension was associated with increased extent of NPs and NFTs in non-demented, middle-aged individuals. Hypertension may cause changes in vessel walls which may lead to hypoperfusion, ischemia, or hypoxia of the brain, and an association between high blood pressure and hippocampal atrophy was only found in individuals not treated for hypertension, and lower NPs and NFTs were found in the brains of subjects who were taking antihypertensive medication and who did not have cerebrovascular disease, suggesting that hypertension medication may have an effect on AD neuropathology. The studies described in this section suggest that the interpretation of results of associations of hypertension with cognition has to be cautious and should take into consideration antihypertensive medication use, APOE genotype, subjects’ age, and the presence of other CVRFs.

**Hypercholesterolemia**

Similarly to the relationships between hypertension and cognitive compromise, most of the studies found total cholesterol measured in midlife to be a significant predictor of subsequent dementia, MCI, or cognitive decline (Table III). Total cholesterol in midlife was also associated with AD in some studies and especially with concomitant hypertension. Studies assessing cholesterol levels later in life have been less consistent in their ability to show a predictive effect for later cognitive decline. Several studies did not find a relationship between cholesterol and dementia or even found an inverse association. Cholesterol was not associated with AD in several studies. The two studies examining MCI as an outcome did not find an association with cholesterol.

The question of association between cholesterol and AD is of particular interest because APOE is the principal cholesterol carrier protein in the brain, the APOE-4 allele is a marker of both increased risk of AD and increased plasma cholesterol concentration. Nonetheless, very few studies report having examined the interactions of cholesterol, APOE genotype, and AD or dementia risk. High cholesterol in late life was associated with higher AD risk in APOE4 noncarriers only, but this association was found only in APOE4 carriers in another study. Moderate decrease in cholesterol from midlife to late life was associated with more impaired cognitive status, especially in APOE4 carriers.
Biochemical and cell biology studies suggest that altered cholesterol metabolism in neurons may underlie pathological processes of AD. Both the generation and clearance of Aβ are regulated by cholesterol. A polymorphism of CYP46, a gene playing a major role in hydroxylation of cholesterol and thereby mediating its removal from the brain, was associated with increased Aβ load in brain tissue. It was also associated with increased Aβ peptides and phosphorylated tau protein in cerebrospinal fluid (CSF). Consistent with this observation, cholesterol was higher with increasing certainty of AD neuropathological diagnosis. However, high cholesterol was not associated with increased neuritic plaques in the neocortex or hippocampus, or with Aβ levels in CSF. Since cholesterol increases atherosclerosis which in turn is associated with dysregulation of cerebral blood flow and hypoperfusion, the effects of cholesterol on dementia risk might not depend only on Aβ mechanisms but also on vascular mechanisms.

Because of some epidemiological studies suggesting an increased risk of dementia in individuals with elevated cholesterol, and because of the biological plausibility underlying this relationship, the protective effect of statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors), among the most widely prescribed cholesterol-lowering medications, was postulated. Prospective epidemiological studies are inconsistent but not contradictory in their results, with several finding that statin use is associated with decreased risk of AD and dementia, and others finding no associations. A Cochrane review concluded that there is no conclusive evidence to recommend statins to reduce the risk of AD, but that there is a growing body of biological and epidemiological evidence suggesting that lowering cholesterol might retard the pathogenesis of AD.

**Inflammation**

Blood elevations of inflammatory markers, specifically C-reactive protein (CRP) and interleukin-6 (IL-6), have been shown to be risk factors for dementia (Table IV). Combination of high levels of several inflammatory markers in the Conselice Study of Brain Aging was associated with increasing hazard ratios for dementia, and specifically high CRP/IL-6 ratios (HR=1.6, 1.03-2.4). As shown in Table IV, high levels of inflammatory markers are also consistently associated with greater rates of cognitive decline. Of interest are the results of the Health, Aging and Body Composition (ABC) study, in which subjects with the metabolic syndrome and high levels of inflammatory markers (IL-6 and CRP) had significantly higher rates of cognitive decline than subjects with the metabolic syndrome but low levels of blood markers of inflammation. The effect of higher IL-6 levels on global and memory function decline was stronger in APOE4 carriers than in non-carriers in the Leiden 85+ study, and was associated with steeper global cognitive decline only in APOE4 carriers in the Rotterdam study. These observations again suggest that interpretation of relationships between inflammation and cognitive compromise have to be cautious and take into consideration of other factors.

| Reference  | Predictor | Results (95% CI) |
|------------|-----------|-----------------|
| Kivipelto  | Midlife   | OR 1.89 (1.02-3.49) for TC>251 mg/dL |
| Whitmer    | Midlife   | HR 1.42 (1.22-1.66) for TC>240 mg/dL |
| Kalmijn     | Midlife   | RR 1.10 (0.95-1.26) for an increase of 1SD of TC |
| Stewart     | Midlife   | No associations with baseline TC but increased risk for men with greater declines in TC |
| Li          | Late life | HR 1.16 (0.81-1.67) for highest 3 TC quartiles compared with lowest |
| Mielke      | Late life | HR 0.31 (0.11-0.85) for highest TC quartiles compared with lowest |
| MCI         |           |                 |
| Kivipelto   | Midlife   | OR 1.9 (1.2-3.0) for TC>6.5 mmol/L |
| Reitz       | Late life | TC was not associated with incident MCI |
| Solfrizzi   | Late life | TC was not associated with incident MCI |
| Cognitive decline | | |
| Solomon     | Midlife   | OR 1.8 (1.1-3.0) for midlife to late life TC decrease of more than 0.5 mmol/L |
| Yaffe       | Late life | OR 1.77 (1.06-2.97) for highest TC quartile compared with lowest |
| Knopman     | Late life | Hyperlipidemia was not associated with decline in delayed recall, digit symbol, or letter fluency |
| Reitz       | Late life | TC was not associated with decline in memory, visuospatial, or language abilities |

**Table III.** Risk of dementia, MCI, and cognitive decline in patients with high total cholesterol (TC). OR, odds ratio, RR, relative risk, HR, hazard ratio
These longitudinal studies are consistent with the in vitro and in vivo studies of neurobiological mechanisms associated with cognitive function, suggesting a potential role of inflammation in the development of cognitive compromise. Several lines of evidence support the importance of inflammation in the pathogenesis of cognitive impairment and AD. Acute-phase proteins, cytokines, chemokines, and their receptors are upregulated in brains of AD patients.\textsuperscript{153} The abundance of activated microglia, the primary neuronal immune surveillance cell, is a relatively early pathogenic event in patients with AD.\textsuperscript{154} Proinflammatory cytokines augment amyloid precursor protein (APP),\textsuperscript{155,156} and in turn, Aβ induces further release of cytokines.\textsuperscript{157} In addition, gene polymorphisms of several inflammatory mediators have been associated with increased risk of AD.\textsuperscript{158} Based on the epidemiological and biological evidence, nonsteroidal anti-inflammatory drugs (NSAIDs) are potential candidate drugs for treatment of AD. However, except for a clinical trial with indomethacin in which beneficial results were found,\textsuperscript{159} trials with NSAIDs show either nonsignificant beneficial trends\textsuperscript{160} or no benefits.\textsuperscript{161-164} The failure of these trials might have been for methodological reasons (short follow-up period, inadequate time of intervention, or insufficient dosing). Examination of anti-inflammation drugs with mechanisms other than cyclooxygenase inhibition is warranted.

Conclusions

The relationships of the four reviewed cardiovascular risk factors with dementia and cognitive decline are complex. Diabetes seems to be the risk factor with the most consistent associations. Composites of the risk factors seem to increase in a dose-dependent fashion the risk for dementia,\textsuperscript{2,3,97} suggesting an accumulating effect of these factors on neuronal stress. In the relatively few studies that have reported interactions of risk factors, they potentiate each other rather than simply accumulating deleterious effects. Moreover, the effect of each of the risk factors discussed in this review seem to depend on APOE genotype. If the underlying biological mechanism

| Study                                      | Predictor | Results (95% CI)                          |
|--------------------------------------------|-----------|-------------------------------------------|
| Dementia                                   | CRP       | OR 2.7 (1.7-4.7) for highest quartile compared with lowest |
| HAAS\textsuperscript{143}                  |           |                                           |
| Conseilce Study of Brain Aging\textsuperscript{144} | CRP       | HR 1.63 (1.10-2.39)                       |
|                                            | ACT       | HR 1.62 (1.10-2.38)                       |
|                                            | IL-6      | No association                            |
| Rotterdam Study\textsuperscript{145}       | CRP       | RR 1.12 (0.99-1.25)                       |
|                                            | IL-6      | RR 1.28 (1.06-1.55)                       |
|                                            | ACT       | RR 1.49 (1.23-1.81)                       |
| Cognitive decline                          | CRP       | RR 2.32 (1.01-5.46) for CRP>5 mg/L decline |
| Helsinki Aging Study\textsuperscript{146}  | IL-6      | OR 2.03 (1.30-3.19) for upper tertile of IL-6. |
| Mac Arthur Studies of Successful Aging\textsuperscript{147} | CRP, IL-6 | RR 1.66 (1.19-2.32) for high CRP and IL-6, and the metabolic syndrome |
|                                            | TNF\textsubscript{α} | No association                           |
| Longitudinal Aging Study Amsterdam\textsuperscript{148} | ACT, CRP, IL-6 | Decline in MMSE but not with other cognitive tests |
|                                            | CRP       | No associations                           |
| Leiden 85+ Study\textsuperscript{139}      | IL-6      | Decline in memory                         |
|                                            | CRP, ACT  | No associations                           |
| Rotterdam Study\textsuperscript{149}       | IL-6      | Decline in memory in APOE4                |
|                                            | CRP, ACT  | No associations                           |
| Edinburgh Artery Study\textsuperscript{150} | IL-6      | Decline in information processing         |
|                                            | Fibrinogen| Decline in nonverbal reasoning            |
|                                            | ICAM-1    | Decline in nonverbal reasoning and global cognition |

Table IV. Risk of dementia, MCI, and cognitive decline in patients with high inflammatory marker levels. CRP, C-reactive protein; IL-6, Interleukin 6; TNF\textsubscript{α}, Tumor necrosis factor \textalpha; ACT-alpha-1-antichymotrypsin; ICAM-1-intercellular adhesion molecule-1 *Subjects with metabolic syndrome and high CRP or IL-6 had the highest risk.
depends on multiple risk factors for its full expression, the apparent effect of a single risk factor would depend on whether the others were present. This may be crucial for understanding the effects on cognition of drugs treating these risk factors. Thus, these considerations may profoundly affect the results of clinical trials and at least partially explain why epidemiological associations are seldom reflected in clinical trials. Epidemiological indications of interactions might suggest subgroups to target in interventional studies.

Los efectos de los factores de riesgo cardiovascular en el compromiso cognitivo

Dado que la expectativa de vida en los Estados Unidos continúa incrementándose, el número proyectado de personas de edad avanzada que desarrollarán demencia crecerá rápidamente. Este artículo revisa cuatro factores de riesgo cardiovascular bien establecidos (diabetes tipo 2, hipertensión, colesterol e inflamación), para los cuales existen evidencias epidemiológicas longitudinales de un riesgo aumentado de demencia, Enfermedad de Alzheimer, deterioro cognitivo leve y decaimiento cognitivo. Estos factores de riesgo son de especial interés ya que son potencialmente modificables, lo que puede influir en la evolución del compromiso cognitivo. La diabetes es el factor de riesgo cardiovascular (FRCv) que se asocia con mayor consistencia con la cognición. La hipertensión en la edad media de la vida está asociada consistentemente con la cognición, pero las asociaciones de esta última con la hipertensión de las etapas tardías de la vida son menos claras. El colesterol total no está asociado consistentemente con la cognición. La interleukina 6 y la proteína C reactiva son marcadores inflamatorios con una asociación relativamente consistente con la cognición. Una combinación de los FRCv aumenta el riesgo para demencia de manera dosis-dependiente, lo que sugiere un efecto acumulativo de estos factores de estrés neuronal. En los relativamente pocos estudios que han dado cuenta de las interacciones entre los factores de riesgo, estos se potencian unos con otros. El efecto de cada uno de los factores de riesgo varía de acuerdo con el genotipo para la apolipoproteína E. Puede ser que el efecto de estos factores de riesgo se modifique según la presencia de los otros, y estas complejas relaciones estén a la base de los mecanismos biológicos del compromiso cognitivo. Para el tratamiento de los factores de riesgo puede ser crucial comprender los efectos que tienen en la cognición los fármacos y otras intervenciones, como el cambio de estilo de vida.

Les effets des facteurs de risque cardiovasculaire sur le déficit cognitif

L’espérance de vie continuant à augmenter aux États-Unis, le nombre de sujets âgés qui développeront une démence est appelé à augmenter rapidement. Cet article examine quatre facteurs de risque cardiovasculaire bien connus (diabète de type 2, hypertension, cholestérol et inflammation) qui ont montré lors d’études épidémiologiques longitudinales qu’ils présentaient un risque accru de démence, de maladie d’Alzheimer, déficit cognitif léger et de déclin cognitif. Ces facteurs de risque sont très intéressants car ils peuvent être modifiés, ce qui pourrait influencer l’évolution du déclin cognitif. Le diabète est le facteur de risque cardiovasculaire (FRCv) le plus régulièrement associé à la cognition. L’hypertension des sujets d’âge moyen semble liée aux capacités cognitives, ce qui apparaît moins important chez les sujets plus âgés. Le cholestérol total n’est pas corrélé à la cognition alors que les marqueurs de l’inflammation interleukine-6 et protéine-réactive C le seraient relativement. Les FRCv augmenteraient le risque de démence de façon dose-dépendante, avec un potentiel effet cumulatif sur le stress neuronal. Dans les relativement rares études qui ont rapporté des interactions des facteurs de risque, ces derniers semblaient se potentialiser les uns les autres. Par ailleurs, l’effet de chacun d’entre eux varierait selon le génotype de l’apolipoprotéine E. L’effet de ces facteurs de risque pourrait varier en fonction de la présence des autres et ces relations complexes sous-tendent les mécanismes biologiques du déficit cognitif. Leur étude apparaît cruciale pour la compréhension des effets des médicaments et d’autres approches thérapeutiques (modification du style de vie) sur la cognition, afin de traiter ces facteurs de risque.
REFERENCES
1. U.S. Census Bureau. Percent Distribution of the Projected Population by Selected Age Groups and Sex for the United States: 2010 to 2050. http://www.census.gov/population/www/projection/summarytables.html. 2008.

2. Ritchie K, Lovestone S. The dementia. Lancet. 2002;360:1759-1766.

3. Rocca WA. Frequency, distribution, and risk factors for Alzheimer’s disease. *Nurs Clin North Am*. 1994;29:101-111.

4. Luchsinger JA, Mayeux R. Cardiovascular risk factors and Alzheimer’s disease. *Curr Atheroscler Rep*. 2004;6:261-266.

5. Schnaidt BM, Goldburt U, Silverman JM, et al. Diabetes mellitus in midlife and the risk of dementia three decades later. *Neurology*. 2004;63:1902-1907.

6. Brayne C, Gao L, Matthews F. Challenges in the epidemiological investigation of the relationships between physical activity, obesity, diabetes, dementia and depression. *Neurobiol Aging*. 2005;26(suppl 1):6-10.

7. Yaffe K, Blackwell T, Kanaya AM, Davidowitz N, Barrett-Connor E, Krueger K. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. *Neurology*. 2004;63:658-663.

8. Ott A, Stolk RP, van HF, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. *Neurology*. 1999;53:1937-1942.

9. Leibson CL, Rocca WA, Hanson VA, et al. The risk of dementia among persons with diabetes mellitus: a population-based cohort study. *Ann N Y Acad Sci*. 1997;826:422-427.

10. Whitemer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. *Neurology*. 2005;64:277-281.

11. Xu W, Qiu C, Winblad B, Fratiglioni L. The effect of borderline diabetes on the risk of dementia and Alzheimer’s disease. *Diabetes*. 2007;56:211-216.

12. Kanaya AM, Barrett-Connor E, Gildengorin G, Yaffe K. Change in cognitive function by glucose tolerance status in older adults: a 4-year prospective study of the Rancho Bernardo study cohort. *Arch Intern Med*. 2004;164:1327-1333.

13. Kalofoutsis C, Piperi C, Zisaki A, et al. Differences in expression of cardiovascular risk factors among type 2 diabetes mellitus patients of different age. *Ann N Y Acad Sci*. 2006;1084:166-177.

14. Strachan MW, Deary IJ, Ewing FM, Frier BM. Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. *Diabetes Care*. 1997;20:438-445.

15. Stewart R, Liolitsa D. Type 2 diabetes mellitus, cognitive impairment and dementia. *Diabet Med*. 1999;16:93-112.

16. Posner HB, Tang MX, Luchsinger J, Lantigiu R, Stern Y, Mayeux R. The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function. *Neurology*. 2002;58:1175-1181.

17. Rotkiewicz-Piorun AM, Al SS, Raji MA, Kuo YF, Markides KS. Cognitive decline in older Mexican Americans with diabetes. *J Natl Med Assoc*. 2006;98:1840-1847.

18. Akomolafe A, Beiser A, Meigs JB, et al. Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. *Arch Neurol*. 2006;63:1551-1555.

19. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ*. 2000;321:405-412.

20. Arvanitakis Z, Schneider JA, Wilson RS, et al. Diabetes is related to cerebrovascular infarction but not to AD pathology in older persons. *Neurology*. 2006;67:1960-1965.

21. Lazarus R, Prettymann R, Cherryman G. White matter lesions on magnetic resonance imaging and their relationship with vascular risk factors in memory clinic attenders. *Int J Geriatr Psychiatry*. 2005;20:274-279.

22. Follich L, Blum-Degen D, Bernstein HG, et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer’s disease. *J Neural Transm*. 1998;105:423-438.

23. Chiu SJ, Chen CM, Cline HT. Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo. *Neuron*. 2008;58:708-719.

24. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. *Arch Neurol*. 2004;61:661-666.

25. Hassing LB, Hofer SM, Nilsson SE, et al. Comorbid type 2 diabetes mellitus and hypertension exacerbates cognitive decline: evidence from a longitudinal study. *Age Ageing*. 2004;33:355-361.

26. van den BE, de Craen AJ, Blesssel GJ, Sussselko J, Westendorp RG. The impact of diabetes mellitus on cognitive decline in the oldest of the old: a prospective population-based study. *Diabetologia*. 2006;49:2015-2023.

27. Janson J, Laedtke T, Parisi JE, O’Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. *Diabetes*. 2004;53:474-481.

28. Cuikerman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies. *Diabetologia*. 2005;48:2460-2469.

29. Xu W, Qiu C, Winblad B, Fratiglioni L. The effect of borderline diabetes on the risk of dementia and Alzheimer’s disease. *Diabetes*. 2007;56:211-216.

30. Kalofoutsis C, Piperi C, Zisaki A, et al. Differences in expression of cardiovascular risk factors among type 2 diabetes mellitus patients of different age. *Ann N Y Acad Sci*. 2006;1084:166-177.

31. Stratman MW, Deary IJ, Ewing FM, Frier BM. Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. *Diabetes Care*. 1997;20:438-445.

32. Stewart R, Liolitsa D. Type 2 diabetes mellitus, cognitive impairment and dementia. *Diabet Med*. 1999;16:93-112.

33. Posner HB, Tang MX, Luchsinger J, Lantigiu R, Stern Y, Mayeux R. The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function. *Neurology*. 2002;58:1175-1181.

34. Rotkiewicz-Piorun AM, Al SS, Raji MA, Kuo YF, Markides KS. Cognitive decline in older Mexican Americans with diabetes. *J Natl Med Assoc*. 2006;98:1840-1847.

35. Akomolafe A, Beiser A, Meigs JB, et al. Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. *Arch Neurol*. 2006;63:1551-1555.

36. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ*. 2000;321:405-412.

37. Arvanitakis Z, Schneider JA, Wilson RS, et al. Diabetes is related to cerebrovascular infarction but not to AD pathology in older persons. *Neurology*. 2006;67:1960-1965.

38. Lazarus R, Prettymann R, Cherryman G. White matter lesions on magnetic resonance imaging and their relationship with vascular risk factors in memory clinic attenders. *Int J Geriatr Psychiatry*. 2005;20:274-279.

39. Follich L, Blum-Degen D, Bernstein HG, et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer’s disease. *J Neural Transm*. 1998;105:423-438.

40. Chiu SJ, Chen CM, Cline HT. Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo. *Neuron*. 2008;58:708-719.

41. Artola A, Kamal A, Ramakers GM, et al. Synaptic plasticity in the diabetic brain: advanced aging? *Prog Brain Res*. 2002;138:305-314.

42. van der Heide LP, Kamal A, Artola A, Gispf WH, Ramakers GM. Insulin modulates hippocampal activity-dependent synaptic plasticity in a N-methyl-d-aspartate receptor and phosphatidylinositol-3-kinase-dependent manner. *J Neurochem*. 2005;94:1158-1166.

43. Plum L, Schubert M, Bruning JC. The role of insulin receptor signaling in the brain. *Trends Endocrinol Metab*. 2005;16:59-65.

44. van der Heide LP, Ramakers GM, Smidt MP. Insulin signaling in the central nervous system: learning to survive. *Prog Neurobiol*. 2006;79:205-221.

45. Unger JW, Livingston JN, Moss AM. Insulin receptors in the central nervous system: localization, signalling mechanisms and functional aspects. *Prog Neurobiol*. 1991;36:343-362.

46. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and
specific mechanisms. *Lancet Neurol.* 2004;3:169-178.

48. Xie L, Helmerhorst E, Taddei K, Plewriight B, Van BW, Martins R. Alzheimer’s beta-amylod peptides compete for insulin binding to the insulin receptor. *J Neurosci.* 2002;22:RC221.

49. Townsend M, Mehta T, Selkoe DJ. Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. *J Biol Chem.* 2007;282:33305-33312.

50. Zhao WQ, De Felice FG, Fernandez S, et al. Amyloid beta oligomers induce impairment of neuronal insulin receptors. *FASEB J.* 2008;22:246-260.

51. Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. *Eur J Pharmacol.* 2004;490:115-125.

52. Solano DC, Sironi M, Bonfini C, Solerte SB, Govoni S, Racchi M. Insulin regulates soluble amyloid precursor protein release via phosphatidylinositol 3 kinase-dependent pathway. *FASEB J.* 2000;14:1015-1022.

53. Gouras GK, Tasi J, Naslund J, et al. Intraneuronal Abeta42 accumulation in human brain. *Am J Pathol.* 2000;156:15-20.

54. Vissarhara H. Intervening in atherogenesis: lessons from diabetes. *Hosp Pract.* 2002;37:29.

55. Dickson DW, Perez M, Colaco C, Avila J. Tau glycation is involved in the aggregation of the protein but not in the formation of filaments. *Cell Mol Biol (Naspy-le-grand)*. 1998;44:1111-1116.

56. Yan SD, Chen X, Fu J, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer’s disease. *Nature.* 1996;382:685-691.

57. Vitek MP, Bhattacharya K, Glendening JM, et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. *Proc Natl Acad Sci U S A.* 1994;91:4766-4770.

58. Smith MA, Taneda S, Richey PL, et al. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. *Proc Natl Acad Sci U S A.* 1994;71:5710-5714.

59. Smith MA, Richey PL, Taneda S, et al. Advanced Maillard reaction end products, free radicals, and protein oxidation in Alzheimer’s disease. *Ann N Y Acad Sci.* 1994;738:447-454.

60. Pedersen KA, McMillan PJ, Kullast JD, Leverenz JB, Craft S, Haynatzki GR. Rosiglitazone attenuates learning and memory deficits in Tg2576 mice. *Exp Neurol.* 2006;199:265-273.

61. Watson GS, Chulleton BA, Regier MA, et al. Preserved cognition in lesions of Alzheimer’s disease. *Neurobiol Aging.* 1996;17:733-743.

62. Lesses MD, Perez M, Colaco C, Avila J. Tau glycation is involved in the aggregation of the protein but not in the formation of filaments. *Cell Mol Biol* (Naspy-le-grand). 1998;44:1111-1116.

63. Yan SD, Chen X, Fu J, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer’s disease. *Nature.* 1996;382:685-691.

64. Risner ME, Saunders AM, Altman JF, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease. *Pharmacogenomics.* 2006;6:246-254.

65. Nissen SE, Wolski K. Effects of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *N Engl J Med.* 2007;356:2457-2471.

66. Craft S, Asthana S, Schellenberg G, et al. Insulin metabolism in Alzheimer’s disease differs according to apolipoprotein E genotype and gender. *Neuroendocrinology.* 1999;70:146-152.

67. Craft S, Asthana S, Cook DG, et al. Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer’s disease: interactions with apolipoprotein E genotype. *Psychoneuroendocrinology.* 2003;28:809-822.

68. Craft S, Asthana S, Schellenberg G, et al. Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer’s disease differ according to apolipoprotein-E genotype. *Ann N Y Acad Sci.* 2000;903:222-228.

69. Craft S, Asthana S, Newcomer JW, et al. Enhancement of memory in Alzheimer disease: insulin and somatostatin, but not glucose. *Arch Gen Psychiatry.* 1999;56:1135-1140.

70. Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D, Jr. Cerebrospinal fluid and plasma insulin levels in Alzheimer’s disease: relationship to severity of dementia and apolipoprotein E genotype. *Neurology.* 1998;50:164-168.

71. Craft S, Newcomer J, Kanne S, et al. Memory improvement following induced hyperinsulinemia in Alzheimer’s disease. *Neurobiol Aging.* 1996;17:123-130.

72. Regner MA, Watson GS, Frey WH, et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. *Neurobiol Aging.* 2006;27:451-458.

73. Benedict C, Hallschmid M, Schultzes B, Born J, Kern W. Intranasal insulin to improve memory function in humans. *Neuroendocrinology.* 2007;86:136-142.

74. Beeri MS, Schneider J, Silverman JM, et al. Insulin combination with other diabetes medication is associated with less Alzheimer’s neuropathology. *Neurology.* In press, 2008;71:750-757.

75. Areosa SA, Grimley EV. Effect of the treatment of Type II diabetes mellitus on the development of cognitive impairment and dementia. *Cochrane Database Syst Rev.* 2002;CD003804.

76. Wu JH, Haan MN, Liang J, Ghosh D, Gonzalez HM, Herman WH. Impact of antidiabetic medications on physical and cognitive functioning of older Mexican Americans with diabetes mellitus: a population-based cohort study. *Ann Epidemiol.* 2003;13:369-376.

77. Launer LJ, Ross GW, Petrovitch H, et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. *Neurobiol Aging.* 2000;21:49-55.

78. Kivipelto M, Helkala EL, Laasko MP, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. *Ann Intern Med.* 2002;137:149-155.

79. Kivipelto M, Helkala EL, Laasko MP, et al. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. *BJU.* 2001;92:1447-1451.

80. Qiu C, von SE, Fastbom J, Winblad B, Fratiglioni L. Low blood pressure and risk of dementia in the Kungsholmen project: a 6-year follow-up study. *Arch Neurol.* 2003;60:223-228.

81. Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. *Lancet.* 1996;347(9099):1141-1145.

82. Ruitenbeek A, Skoog I, Ott A, et al. Blood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg H-70 Study. *Dement Geriatr Cogn Disord.* 2001;12:33-39.

83. Kalmijn S, Foley D, White L, et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study. *Arterioscler Thromb Vasc Biol.* 2000;20:2255-2260.

84. Kivipelto M, Helkala EL, Hanninen T, et al. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. *Neurology.* 2001;56:1683-1689.

85. Tzourio C, Dufouil C, Ducimetiere P, Alperovitch A. Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. *EVA Study Group. Epidemiology of Vascular Aging. Neurology.* 1999;53:1948-1952.

86. Mielke MM, Rosenberg PB, Tschanz J, et al. Vascular factors predict rate of progression in Alzheimer’s disease. *Neurology.* 2007;68:1850-1858.

87. Hebert LE, Scherr PA, Bennett DA, et al. Blood pressure and late-life cognitive function change: a biracial longitudinal population study. *Neurology.* 2004;62:2011-2024.

88. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, eur R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. *Neurology.* 2005;65:545-551.

89. Yamada M, Mimori Y, Kasagi F, et al. Incidence of dementia, Alzheimer disease, and vascular dementia in a Japanese population: Radiation Effects Research Foundation adult health study. *Neuroepidemiology.* 2008;30:152-160.

90. Shah RC, Wilson RS, Bienias JL, Arvanitakis Z, Evans DA, Bennett DA. Relation of blood pressure to risk of incident Alzheimer’s disease and change in global cognitive function in older persons. *Neuroepidemiology.* 2006;26:30-36.

91. Skoog I, Andreasson LA, Landahl S, Lernfelt B. A population-based study on blood pressure and brain atrophy in 85-year-olds. *Hypertension.* 1998;32:404-409.

92. Heijer T, Skoog I, Oudkerk M, et al. Association between blood pressure levels over time and brain atrophy in the elderly. *Neurobiol Aging.* 2003;24:307-313.
93. Guo Z, Fratiglioni L, Zhu L, Fastbom J, Winblad B, Viitanen M. Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use. Arch Neurol. 1999;56:991-996.

94. Khachatryan AS, Zandi PP, Lyketsos CG, et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol. 2006;63:686-692.

95. Hajar J, Catone H, Sixta S, et al. Cross-sectional and longitudinal association between antihypertensive medications and cognitive impairment in an elderly population. J Gerontal A Biol Sci Med. 2005;60:67-73.

96. Guo Z, Fratiglioni, Viitanen M, et al. Apolipoprotein E genotypes and the incidence of Alzheimer’s disease among persons aged 75 years and older: variation by use of antihypertensive medication? J Am Geriatr Soc. 2001; 1:153:225-231.

97. Peila R, White LR, Masaki K, Petrovitch H, Launer LJ. Reducing the risk of dementia: efficacy of long-term treatment of hypertension. Stroke. 2006;37:1165-1170.

98. Oiu C, Winblad B, Fastbom J, Fratiglioni L. Combined effects of APOE genotype, blood pressure, and antihypertensive drug use on incident AD. Neurology. 2003; 9:6:655-660.

99. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP), SHEP Cooperative Research Group. JAMA. 1991;265:3255-3264.

100. Applegate WB, Pressel S, Wittes J, et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. Arch Intern Med. 1994;154:2154-2160.

101. Prince MJ, Bird AS, Blizard RA, Mann AH. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. BMJ. 1996;312:801-805.

102. Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002;162:2046-2052.

103. Litthel H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875-886.

104. Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008;7:683-689.

105. den HT, Launer LJ, Prins ND, et al. Association between blood pressure, white matter lesions, and atrophy of the medial temporal lobe. Neurology. 2005;65:263-267.

106. Vermeer SE, Prins ND, den Heijger HT, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215-1222.

107. Petrovitch H, White LR, Izmirlian G, et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging Study. Neurobiol Aging. 2000;21:57-62.

108. Sparks DL, Scheff SW, Liu H, Landers TM, Coyne CM, Hunisaker JC, III. Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. J Neurol Sci. 1995;131:162-169.

109. de la Torre JC. Cerebral hyperperfusion, capillary degeneration, and development of Alzheimer disease. Alzheimer Dis Assoc Disord. 2000;14 Suppl 1:572-581.

110. Jendroska K, Poeoe W, Daniel SE, et al. Ischemic stress induces deposition of amyloid beta immunoreactivity in human brain. Acta Neuropathol. 1995;90:461-466.

111. de la Torre JC. Critically attained threshold of cerebral hyperperfusion: can it cause Alzheimer’s disease? Ann N Y Acad Sci. 2000;903:424-436.

112. Kalbck W, Esh C, Castano EM, et al. Atherosclerosis, vascular amyloidosis and brain hyperfusion in the pathogenesis of sporadic Alzheimer’s disease. Neurol Res. 2004;26:525-539.

113. Korf ES, White LR, Schelten P, Launer LJ. Midlife blood pressure and the risk of hippocampal atrophy: the Honolulu Asia Aging Study. Hypertension. 2004;44:29-34.

114. Hoffman LB, Schmeider J, Lesser GT, et al. Less Alzheimer’s disease neuropathology in medicated hypertensive than non hypertensive persons. Neurology. 2009. In press.

115. Solomon A, Kareholt I, Ngandu T, et al. Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology. 2007;68:751-756.

116. Stewart R, White LR, Xue QL, Launer LJ. Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu-Asia Aging Study. Arch Neurol. 2007;64:103-107.

117. Li G, Shofer JB, Kukull WA, et al. Serum cholesterol and risk of Alzheimer disease: a community-based cohort study. Neurology. 2005;65:1045-1050.

118. Mielke MM, Zandi PP, Sjogren M, et al. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology. 2005;64:1689-1695.

119. Reitz C, Tang MX, Manly J, Schupf N, Mayeux R, Luchsinger JA. Plasma lipid levels in the elderly are not associated with the risk of mild cognitive impairment. Dement Geriatr Cogn Disord. 2008;25:232-237.

120. Solfrizzi V, Panza F, Colacino AM, et al. Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology. 2004;63:1882-1891.

121. Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol. 2002;59:378-384.

122. Reitz C, Luchsinger J, Tang MX, Manly J, Mayeux R. Impact of plasma lipids and time on memory performance in healthy elderly without dementia. Neurology. 2005;65:1378-1383.

123. Notkola IL, Sulkava R, Pekkanen J, et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer’s disease. Neuroepidemiology. 1998;17:14-20.

124. Tan ZS, Seshadri S, Beiser A, et al. Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. Arch Intern Med. 2003;163:1053-1057.

125. Reitz C, Tang MX, Luchsinger J, et al. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol. 2004;61:705-714.

126. Roman MJ, Tang MX, Berglund L, et al. APOE genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology. 1999;53:517-521.

127. Puglielli L, Tanzi RE, Kovacs DM. Alzheimer’s disease: the cholesterol connection. Nat Neurosci. 2003;6:345-351.

128. Evans RM, Emsley CL, Gao S, et al. Serum cholesterol, APOE genotype, and the risk of Alzheimer’s disease: a population-based study of African Americans. Neurology. 2000;54:240-242.

129. Hall K, Murrell J, Ogunniyi A, et al. Cholesterol, APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian Youuba. Neurology. 2006;66:223-227.

130. Papassotiropoulos A, Streffer JR, Tsolaki M, et al. Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intrinsic CYP46 polymorphism. Arch Neurol. 2003;60:29-35.

131. Lesser GT, Haroutunian V, Purohit DP, et al. Serum lipids are related to Alzheimer’s pathology in nursing home residents. Dement Geriatr Cogn Disord. 2009;8:27;42-49.

132. Lesser G, Kandiah K, Libow LS, et al. Elevated serum total and LDL cholesterol in very old patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2001;12:138-145.

133. Launer LJ, White LR, Petrovitch H, Ross GW, Curb JD. Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology. 2001;57:1447-1452.

134. Fassbender K, Stroich M, Bertsch T, et al. Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology. 2002;59:1257-1258.

135. Hofman A, Ott A, Breteler MM, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam Study. Lancet. 1997;349(9046):151-154.

136. Bradbury J, How NSAlDS might prevent Alzheimer’s disease. Lancet Neurol. 2004;3:638.

137. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry. 2009;80:13-17.
Clinical research

138. Sparks DL, Kryscio RJ, Sabbagh MN, Connor DJ, Sparks LM, Liebsack C. Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr Alzheimer Res. 2008;5:416-421.

139. Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology. 2008;71:344-350.

140. Arvanitakis Z, Schneider JA, Wilson RS, et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology. 2008;70:1795-1802.

141. Li G, Higdon R, Kukull WA, et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology. 2004;63:1624-1628.

142. Scott HD, Laake K. Statins for the prevention of Alzheimer's disease. Cochrane Database Syst Rev. 2001:CD003160.

143. Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol. 2002;52:168-174.

144. Ravaglia G, Forti P, Maioli F, et al. Blood inflammatory markers and risk of dementia: The Conselice Study of Brain Aging. Neurobiol Aging. 2007;28:1810-1820.

145. Engelhart MJ, Geerlings MI, Meijer J, et al. Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. Arch Neurol. 2004;61:668-672.

146. Tilvis RS, Kahonen-Vare MH, Jolkkonen J, Valvanne J, Pitkala KH, Strandberg TE. Predictors of cognitive decline and mortality of aged people over a 10-year period. J Gerontol A Biol Sci Med Sci. 2004;59:268-274.

147. Weaver JD, Huang MH, Albert M, Harris T, Rowe JW, Seeman TE. Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology. 2002;59:371-378.

148. Yaffe K, Lindquist K, Penninx BW, et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology. 2003;61:76-80.

149. Yaffe K, Kanaya A, Lindquist K, et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA. 2004;292:2237-2242.

150. Schram MT, Euser SM, de Craen AJ, et al. Systemic markers of inflammation and cognitive decline in old age. J Am Geriatr Soc. 2007;55:708-716.

151. Rafnsson SB, Deary IJ, Smith FB, et al. Cognitive decline and markers of inflammation and hemostasis: the Edinburgh Artery Study. J Am Geriatr Soc. 2007;55:700-707.

152. Weisman D, Hakimian E, Ho GJ. Interleukins, inflammation, and mechanisms of Alzheimer’s disease. Vitam Horm. 2006;74:505-530.

153. Elkeelenboom P, Bate C, van Gool WA, et al. Neuroinflammation in Alzheimer's disease and prion disease. GLia. 2002;40:232-239.

154. Brugg B, Dubreuil YL, Huber G, Wollman EE, haye-Bouchaud N, Mariani J. Inflammatory processes induce beta-amyloid precursor protein changes in mouse brain. Proc Natl Acad Sci U S A. 1995;92:3032-3035.

155. Sheng JG, Bora SH, Xu G, Borchelt DR, Price DL, Koliatos VE. Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswt transgenic mice. Neurobiol Dis. 2003;14:133-145.

156. McGeer PL, McGeer EG. Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging. 2001;22:799-809.

157. Vasto S, Candore G, Duro G, Lio D, Grimaldi MP, Caruso C. Alzheimer's disease and genetics of inflammation: an pharmacogenomic vision. Pharmacogenomics. 2007;8:1735-1745.

158. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 1993;43:1609-1611.

159. Scharf S, Mander A, Ugioni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease. Neurology. 1999;53:197-201.

160. Aisen PS, Scharer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003 4;289:2819-2826.

161. Aisen PS, Schneider J, Pasinetti GM. Randomized pilot study of nimesulide treatment in Alzheimer’s disease. Neurology. 2002 9;58:1050-1054.

162. Sainati SM, Ingram DM, Talwalker S, Geis GS. Results of a double-blind, placebo-controlled study of celecoxib for the progression of Alzheimer’s disease. Paper presented at: Sixth International Stockholm-Springfield Symposium on advances in Alzheimer therapy. Stockholm, Sweden; 2000.

163. Martin BK, Szekely C, Brandt J, et al. Cognitive function over time in the Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol. 2008;65:896-905.